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Early gastrointestinal cancers are defined as lesions 
limited to the mucosa or submucosa without invading 
the muscularis propria, regardless of the presence of 
lymph node metastases. Although the natural history 
of these diseases is basically alike worldwide, its 
management is quite different between the East and 
West; aggressive surgery is frequently adopted by 
Western surgeons, while less invasive techniques are 
adopted by Asian colleagues. These techniques in-
clude endoscopic mucosal resection and endoscopic 
submucosal dissection which are now accepted as 
treatments for early gastrointestinal cancers in se-
lected cases. Recent advances in endoscopic de-
tection and treatment techniques, especially in Japan 
and Korea, have prompted Western endoscopists to 
learn these techniques. This review addresses recent 
advances regarding endoscopic resections of early 
gastrointestinal cancers, which promoted its use in 
Western countries. In addition, prospective studies on 
endoscopic resection in Western countries are also 
described. (Gut and Liver 2007;1:12-21)
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INTRODUCTION
  Therapeutic endoscopy plays a major role in the man-
agement of gastrointestinal (GI) neoplasia. Its indications 
can be generalized into four broad categories; (i) to re-
move or obliterate neoplastic lesion, (ii) to palliate malig-
nant obstruction, (iii) to treat bleeding, and (iv) the 
others.1,2 Only endoscopic resection allows complete his-
tological staging of the cancer, which is critical as it al-
lows stratification and refinement for further treatment. 
Although other endoscopic techniques such as ablation 
therapy may also cure early GI cancer, they can not pro-
vide a definitive pathological specimen.
  Early stage lesions reveal low frequency of lymph node 
metastasis which allows for less invasive treatments and 
thereby improving the quality of life when compared to 
surgery.3 Endoscopic mucosal resection (EMR) and sub-
mucosal dissection (ESD) are now accepted worldwide as 
treatment modalities for early cancers of the GI tract.1-3 
Recent advances in endoscopic detection and treatment 
techniques in Japan and Korea have prompted Western 
endoscopists to use EMR and ESD as elective treatment 
modalities in selected cases. However, they are still chal-
lenging techniques and require considerable experience. 
  Following possible explanations are proposed why EMR 
and ESD are less often performed in West; (i) the screen-
ing system for these diseases, (ii) the relative infrequency 
of gastric and esophageal cancers and their premalignant 
precursors, (iii) the differences in the judging criteria be-
tween Japanese and Western pathologists, and (iv) the 
risk perception of the procedures.4 The purpose of this 
review was to examine the recent advances in the endo-
scopic resection of early GI cancers in Western countries.
Review
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Table 1. The Endoscopic Classification of Early Gastroin-
testinal Cancers
Shape Classification
Protruding
  Pedunculated 0-Ip
  Sessile 0-Is
Neither protruding nor excavated
  Slightly elevated 0-IIa
  Completely flat 0-IIb
  Slightly depressed 0-IIc
  Elevated and depressed 0-IIc+IIa
Excavated
  Ulcerated 0-III
  Excavated and depressed 0-IIc+III or 0-III+IIc
Fig. 1. Histological diagnosis of EGC. (A) A small depressed lesion is noticed on the posterior wall of upper gastric body. (B) 
Lesion without invasive finding is noticed on the biopsy, which is classified as dysplasia (Vienna classification 4.1.) in the West. In
contrast, this lesion is classified as well differentiated adenocarcinoma (Vienna classification 4.2.) in Japan. (C) After the resection, 
submucosally invasive adenocarcinoma with lymphatic involvement (Vienna classification 5.2.) is diagnosed.
DETECTION OF EARLY GASTROINTESTINAL 
CANCERS
  Early GI cancers (except the esophagus) are defined as 
being limited to the mucosa or submucosa but not invad-
ing the muscularis propria, regardless of the presence of 
lymph node metastases. A macroscopic classification of 
these lesions was first established by Japanese endo-
scopists (Table 1). It was ratified at the Paris workshop 
in 2002 and has now been accepted worldwide.5 Usually, 
early cancers are detected as 0-I and 0-III types in most 
of the world, but widespread use of chromoendoscopy, 
anti-foaming agents, and newer imaging methods have en-
abled identification of superficial lesions such as faint 
mucosal irregularity or discoloration, which had pre-
viously overlooked. Over 50% of cancers diagnosed in 
Japan are early cancers while its frequency is only 10% in 
the West.6 
1. Endoscopic detection
  Detection and diagnosis of early GI cancer can be diffi-
cult because of the less well defined subtle findings. 
These may include slight differences in color (i.e., more 
red or pale), loss of vascularity, nodularity, thickening, or 
depression.6 Thus, apart from searching for protrusion, 
erosion, ulceration, and depression, examination for early 
GI cancer requires continuous search for mucosa with fea-
tures distinct from those of its surrounding.5 Therefore, 
the subtleties of endoscopic findings of early GI cancer 
require patient preparation to be most optimal. Effective 
methods to increase visualization of the mucosa of the 
upper gastrointestinal tract (UGI) include the usage of 
pronase, a proteolytic enzyme solution, to remove mucus. 
  Chromoendoscopy is an important adjunct technique to 
enhance visualization of superficial early cancers and to 
define their borders. Indigo carmine solution (0.2%), a 
contrast dye, is commonly used in the stomach to high-
light the contours and topography of the lesion by enter-
ing mucosal depressions and crevices thus enabling the 
biopsy of the minute lesions. Recently, narrow band im-
age (NBI) and autofluorescence images (AFI) are in-
troduced as a virtual chromoendoscopy.
2. Histological diagnosis
  Apart from the diagnostic difficulty of biopsy as a rea-
son for the low incidence of early GI cancer in the West, 
different histological criteria between the West and Japan 
would be another reason.7 For example, most mucosal 
cancer of the intestinal type in Japan is not diagnosed as 
cancer in the West (Fig. 1). There are large discrepancies 
in the diagnostic criterion between the Western and 
Japanese pathologist. These differences have caused con-
siderable problems in the interpretation of Japanese can-
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Table 2. Vienna Classification of Gastrointestinal Epithelial 
Neoplasia
Category Treatment
1 - Negative for neoplasia/dysplasia No treatment 
2 - Indefinite for neoplasia/dysplasia Follow up
3 - Noninvasive low grade dysplasia Follow up
    (low grade adenoma/dysplasia)
4 - Noninvasive high grade dysplasia Endoscopic 
  4.1 - High grade adenoma  resection,
  4.2 - Noninvasive carcinoma  surgery
       (carcinoma in situ)
  4.3 - Suspicion of invasive carcinoma
5 - Invasive neoplasia Surgery 
  5.1 - Intramucosal carcinoma  (recently ESD)
  5.2 - Submucosal carcinoma or beyond
ESD, endoscopic submucosal dissection.
Fig. 2. Standard EMR methods. (A) Snare polypectomy, (B) 
strip biopsy, (C) EMR with cap technique, and (D) EMR with 
ligation technique.
cer research by Western clinicians and researchers. Carci-
noma is defined as invasion with submucosal layer, mus-
cularis mucosa, or at least lamia propria in the West. 
However, in Japan, cellular atypia and structural atypia is 
also considered as GI neoplasia regardless of invasive 
findings. 
  The differences between the Western and Japanese his-
tological classifications of GI epithelial neoplastic lesions 
have been largely resolved by adopting the Vienna classi-
fication (Table 2).7 Non-invasive neoplasia include low- 
and high-grade dysplasia (LGD and HGD) in which the 
basement membrane is not infiltrated. Invasive lesions in-
clude intramucosal neoplasia infiltrating the submucosa. 
To quantify the risk of lymph node metastases, mucosal 
(m) and submucosal (sm) layers have each been divided 
into three sections: m1 (epithelium), m2 (lamina prop-
ria), and m3 (muscularis mucosae) and sm1, sm2, and 
sm3. In addition, sm1 is subclassified into a, b, and c ac-
cording to the degree of horizontal extension. It is the 
depth that mainly determines the necessity of inter-
vention. 
  The depth of invasion is measured microscopically and 
the risk of lymph node metastasis is known to be related 
with a defined micrometric cutoff. In squamous cell carci-
noma (SCC) of the esophagus, when infiltration is less 
than 200μm, the risk of nodal metastases is low.8 For 
early adenocarcinoma in Barrett's esophagus (BE) and ear-
ly gastric cancer (EGC), a submucosal infiltration micro-
metric cutoff of 500μm has been proposed, as the risk of 
nodal metastases appears low.9 In contrast, a 20-25% risk 
of node involvement with submucosal infiltration in 
Barrett's cancer has been reported in the West.10 In the 
colorectum, the risk of lymph node metastasis is negli-
gible when the tumor invasion is less than 1,000μm.11 
Other factors, such as the degree of differentiation and 
the presence of vascular or lymphatic invasion are also re-
lated to the risk of lymph node metastasis.
ENDOSCOPIC TREATMENT OF EARLY GAST-
ROINTESTINAL CANCERS IN THE WEST
  The treatment of early GI cancers in the West is still 
mainly an operation. However, many Western endo-
scopists are now learning from the Japanese experiences 
and increasingly adopting endoscopic resection (Fig. 2). 
In contrast to Japan and Korea, there has so far been only 
limited experience in Europe as well as in US. Here, we 
report the latest and largest prospective series so far in 
Western countries with early GI cancers, treated by EMR 
or ESD. 
1. Esophagus
  Multiple synchronous lesions as well as metachronous 
lesions have been reported up to 31% of patients in 
esophageal SCC.12 Five-year survival rate is up to 95% af-
ter EMR in patients with superficial SCC without lymph 
node metastasis in m1 and m2 SCC of the esophagus.13 
Recently, an expanded indications for EMR in patients 
with superficial esophageal carcinoma m3 or sm1 has 
been proposed.14 
  A study from Germany, consisted of 12 HGD and 53 
mucosal SCC of the esophagus, reported on the treatment 
using a ligation EMR technique.15 This was the first 
Western study which showed similar results to those of 
the Japan in early esophageal SCC. They reported that 
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Table 3. Indications for Endoscopic Mucosal Resection / Endoscopic Submucosal Dissection in Early Gastrointestinal Cancers
Esophagus Stomach Colorectum
• Well or moderately differentiated • Well and/or moderately differentiated AC and/or • Well or moderately
  SCC-AC   papillary carcinoma   differentiated AC
• IIa, IIb, IIc ＜20 mm  • Cancer confined to mucosa or IMC IIa ＜20 mm • Cancer confined to
• m1 or m2 cancers • Cancer confined to mucosa or IMC IIb, IIc ＜10 mm   mucosa or IMC IIa ＜20 mm
• Without evidence of venous or • Without evidence of venous or lymphatic involvement • Cancer confined to mucosa
  lymphatic involvement • Regardless of tumor size without ulcer finding   or IMC IIb, IIc ＜10 mm
• Involvement of ＜1/3 of the   (expanded criteria) • Superficially invading the
  circumference (stricture formation) • ≤30 mm in size with ulcer finding (expanded criteria)   submucosa (＜500μ from 
• HGD and IMC in  • Undifferentiated IMC, no lymphovascular   the muscularis mucosa)
  Barrett's esophagus   invasion, without ulcer findings, ≤20 mm • Laterally spreading
   • Minute submucosal cancer (sm1) ≤30 mm   tumors
    in size (expanded criteria)
SCC, squamous cell carcinoma; AC, adenocarcinoma; HGD, high grade dysplasia; IMC, intramucosal cancer.
complete resection was achieved in 11/12 patients of 
HGD and 51/53 patients of mucosal SCC. Although re-
currence was observed in 16 patients after EMR, the le-
sions were completely resected after further endoscopic 
treatment. Complications occurred in 15/65 patients all 
being esophageal strictures which were successfully man-
aged by endoscopy. Seven year survival rate was 77%.
2. Barrett's esophagus
  Endoscopic therapy aims to remove the dysplastic 
Barrett's epithelium allowing restoration of squamous 
epithelium. EMR could be a therapeutic alternative to 
surgical esophagectomy which carries substantial morbid-
ity and mortality.16 When HGD is diagnosed in short seg-
ment BE (BE shorter than 30 mm in length), EMR would 
be considered to remove all the metaplastic epithelium. A 
study from US reported that visible areas of HGD in long 
segment BE (BE longer than 30 mm in length) may be 
removed by EMR, followed by photodynamic therapy to 
destroy invisible foci.17 Although strictures occurred in 
30% of patients, 17 superficial esophageal cancers were 
removed by combining EMR and photodynamic therapy.
  A study from Germany reported that circumferential 
EMR was carried out by using a simple snare technique 
without a cap in 12 patients with BE containing multi-
focal high-grade intraepithelial neoplasia or intramucosal 
cancer.18 Five had multifocal lesions while two developed 
strictures that required bougienage. There was no re-
currence during the median follow-up of 9 months. 
Similar study from France reported on circumferential 
EMR performed in 21 patients with HGD or mucosal 
cancer.19 Three patients needed additional therapy such as 
surgery or chemotherapy due to residual disease after the 
endoscopic resection. In addition, two local recurrences 
were retreated by EMR. 
  A study from Netherlands, consisted of 77 esophagec-
tomy specimens containing HGD or T1 adenocarcinoma, 
reported that lymph node metastasis occurred in 23% 
sm2 and 69% sm3 tumors, but not in m1, m2, m3, and 
sm1 lesions.20 They concluded that m1, m2, m3, and sm1 
lesions could be treated endoscopically if the lesions are 
less than 30 mm, well differentiate type adenocarcinoma, 
and without lymphangitic invasion. However, care must 
be taken with the intitial diagnosis of endoscopic biopsy 
since significant changes in diagnosis occur after EMR 
such as downgrading from HGD to BE without dysplasia 
or being reclassified from benign to malignant diagnosis.21 
A study from Germany reported that suck-and-cut EMR 
technique was performed in 100 consecutive patients with 
low-risk adenocarcinoma of the esophagus arising from 
BE, and complete local remission was achieved in 99/100 
patients.22 During the mean follow-up period of 36.7 
months, recurrent or metachronous carcinomas were 
found in 11% of the patients, but were successfully treat-
ed by repeated EMR. Five-year survival rate was 98%.
3. Stomach
  EMR and ESD are established as an alternative treat-
ment to surgery for EGC in Japan.23 Criteria for endo-
scopic therapy are; (i) elevated type intramucosal cancer 
(0 to IIa) less than 20 mm, (ii) depressed type mucosal 
cancer without ulceration (0 to IIb, 0 to IIc) less than 10 
mm, and (iii) well differentiated or moderately differ-
entiated intestinal type adenocarcinoma. Recently, an ex-
tended indication for EMR in EGC has been proposed; (i) 
well differentiated cancers less than 30 mm without ulcer 
or ulcer scar, (ii) mucosal cancers less than 20 mm with 
ulcer or ulcer scar, (iii) sm1 cancer less than 20 mm 
without ulcer or ulcer scar, and (iv) poorly differentiated 
cancer less than 10 mm.24 The risk of node metastasis is 
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about 0.4% for differentiated cancers while it is about 4% 
in undifferentiated mucosal cancers.25 In another report, 
poorly differentiated and signet ring cell carcinomas less 
than 5 mm in size would be considered for EMR or 
ESD.26 In addition, the risk of lymph node metastasis in 
additional groups of patients with EGC was defined in 
Japan by using a large database involving more than 
5,000 patients who underwent gastrectomy with R2 level 
lymph node dissection.25 The results of this study led to 
an expanded list of candidates suitable for endoscopic re-
section including lesions larger than 21 mm and ulcer-
ative lesions which were originally resected by surgery 
(Table 3). Although the need for gastrectomy in EGC can 
be reduced by expanding the criteria for EMR, it is diffi-
cult to resect large and ulcerative lesions by conventional 
EMR. Therefore, substantial experience has been gained 
and ESD using the IT knife (Fig. 3) became a standard 
practice in Japan for the treatment of EGC (Fig. 4).27 
  In Europe, there is a report from Germany on ESD us-
ing a new double-channel endoscope (the R-scope).28 
After the resection, surgery was performed in 4/10 pa-
tients because of perforation, incomplete resection or 
deep submucosal tumor infiltration.
4. Duodenum
EMR has been used for ampullary and peri-ampullary ne-
oplasias and sub-epithelial lesions including stromal cell 
tumors, cysts, and neuroendocrine tumors. Although en-
doscopic resection can provide a wide tumor resection 
with a negative resection margin, it is not yet recom-
mended as a curative therapy for early stage ampulla of 
Vater cancer because of the high lymphovascular invasion 
rate.29 A study from US reported a higher risk of bleeding 
(33%) among 27 duodenal EMR afer complete resec-
tion.30 
5. Submucosal tumor
  EMR technique may also be applied to submucosal tu-
mors in order to achieve histologic diagnosis and to ach-
ieve complete removal. In Germany, complete resection 
was achieved in 19/20 patients with submucosal esoph-
ageal tumors using a rubber band or a simple snare.31 
Bleeding occurred in 40% of the cases and was success-
fully managed by endoscopic hemostasis. Rosch et al at-
tempted endoscopic en bloc resection of mucosal and 
submucosal tumors of the UGI tract, using the IT knife.32 
In this pilot series, complete removal was achievied in 
25% of the mucosal and 36% of the submucosal lesions 
of 37 lesions; 13 in esophagus, 24 in stomach and 1 in 
duodenum. Perforation occurred in one case, and was 
managed conservatively with endoscopic clipping.
  In US, variously located superficial neoplastic or sub-
mucosal lesions were treated by EMR using strip biopsy 
or suction cap techniques after the evaluation with 
high-frequency (20 MHz) ultrasonography.33 Wide variety 
of tumors including flat colonic adenomas, gastric and 
Fig. 3. Endoscopic devices for ESD. (A) IT knife (KD-610L, Olympus), (B) modified IT knife 
with three-pointed star blade (Olympus), (C) Needle knife (KD-1L-1, Olympus), (D) Hook 
knife (KD-620LR, Olympus), (E) Flex knife (KD-630L, Olympus), (F) Triangle-tip knife 
(Olympus), (G) Flash knives with several length of needle (Fujinon Toshiba ES systems), (H) 
Mucosectom (DP-2518, Pentax), and (I) Small caliber tip transparent (ST) hood (DH-15GR, 
15CR, Fujinon Toshiba ES systems).
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Fig. 4. ESD procedures. (A) A depressed type EGC is noticed on the anterior wall of the antrum. (B) Indigo carmine dye is sprayed 
to detect the tumor boarder. (C) Markings are done by needle knife with coagulation current. (D) Mucosal cutting is done with IT
knife using ENDO-CUT mode. (E) Dissecting submucosal layer is done by the aid of IT knife with ENDO CUT mode. Attachment
cap is applied to stretch submucosal tissue. (F) A large ESD defect is noticed after complete one piece resection without perforation.
(G) Flattened ESD specimen is fixed with thin needles on plate.
rectal neoplasms, ampullary adenomas, duodenal carci-
noids, BE, and esophageal cancers including 24 epithelial 
lesions and 8 submucosal lesions were treated success-
fully. All lesions were completely resected except in one 
duodenal bulb carcinoid tumor. Minor complications such 
as pain and mild pancreatitis occurred in three cases. Six 
out of seven carcinomas revealed no recurrence during 
the mean follow-up of 12 months.
6. Colorectum
  EMR and ESD are being successfully used for ear-
ly-stage colon cancers, flat adenomas, large superficial col-
orectal tumors, and rectal carcinoids.34 Lymph node meta-
stasis in T1 colorectal carcinoma occurs only after in-
filtrating submucosa and is correlated to the depth of 
submucosal penetration by the tumor.35 This supports the 
therapeutic effectiveness of endoscopic removal of polyps 
and flat lesions that are confined to the mucosa, regard-
less of their size. On the other hand, colorectal laterally 
spreading tumor (LST) classified as granular (LST-G) and 
non granular type (LST-NG), are defined as lesions larger 
than 10 mm in diameter, with a low vertical axis, extend-
ing along the luminal wall.36 For en bloc resection of flat 
lesions larger than 20 mm, conventional EMR is in-
adequate because of incomplete removal and frequent lo-
cal recurrence. When analyzing the endoscopic features of 
257 LSTs in order to assess which features correlated 
with the depth of invasion, unevenness of nodules, pres-
ence of large nodules, size, histological type, and presence 
of depression in the tumor were significantly associated 
with the depth of invasion.36 In addition, LST-NG showed 
a higher frequency of sm invasion than LST-G (14% vs. 
7%).37 Presence of a large nodule in LST-G type was as-
sociated with higher sm invasion while pit pattern, scle-
rous wall change, and larger size were significantly asso-
ciated with higher sm invasion in LST-NG type. There-
fore, it is advisable to perform endoscopic piecemeal re-
section for LST-G type with the area including the large 
nodule resected first. Besides, LST-NG type should be re-
moved by en bloc resection because of the higher poten-
tial of sm invasion when compared to that of the LST-G 
type.37 
  In aspect of Western experiences, a study from 
Germany reported that complications occurred in two pa-
tients of 57 patients after EMR in large colorectal neo-
plasia between 10 mm and 50 mm.38 Recurrence rate fol-
lowing EMR range from 0% to 40% which could be re-
duced when combined by argon plasma coagulation.39,40 
However, a recent study from Poland revealed that argon 
plasma coagulation did not reduce the recurrence rate 
compared to polypectomy alone.41 Besides, a study from 
Italy reported that EMR was performed for 139 SP in 136 
patients by snare polypectomy, and invasive carcinoma 
was found in 17 cases.42 After 12 months of follow up af-
ter EMR, no local recurrence was detected in 7 patients 
with invasive carcinoma without surgery. Another study 
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from UK reported on 30 large colorectal polyps which 
were treated by en bloc resection in 22 cases and by 
piecemeal resection in 8 cases.43 Histologically, the le-
sions were predominantly adenomatous polyps, but 7 cas-
es revealed incidental focus of adenocarcinoma. Although 
bleeding occurred in two cases, there was no bowel 
perforation. There was no evidence of recurrence during 
the median follow-up of 21 months. 
  In a prospective cohort study in Italy, IT knife was used 
for EMR of large colorectal polyps larger than 3 cm 
which are unsuitable for standard polypectomy.44 The re-
sults showed the likelihood of complete en bloc resection 
of mucosal lesions improved by new approach with IT 
knife when compared with previous studies on colonic 
EMR, even for lesions located in difficult positions or 
larger than 30 mm. En bloc resection was achieved only 
in 55.1% of the lesions and piecemeal resection was per-
formed in the rest of the cases. Although complete tumor 
removal was achieved in 19 patients, 13 had LGD, 15 had 
HGD, and one had a tumor invading the submucosa. 
Complications occurred in four patients which were all 
managed conservatively. Local recurrences were detected 
in five patients and were treated by argon plasma coagu-
lation and snare polypectomy. There was no recurrence 
during the median follow-up period of 15.7 months.44
MANAGEMENT AFTER ENDOSCOPIC RESEC-
TION
  After the retrieval, resected specimen is flattened and 
fixed on the board (Fig. 4). Additional resections and re-
constructions are seldom necessary as long as the mark-
ing dots are completely included in en bloc resection. 
Accurate evaluation of the resected specimen should be 
achieved immediately after the removal before being im-
mersed in formaldehyde. Orientation of the specimen is 
accomplished by fixing its periphery with thin needles in-
serted into an underlying plate of rubber or wood. The 
submucosa side of the specimen is apposed to the plate.
  After the fixation, the specimen should be sectioned se-
rially in 2 mm intervals parallel to a line that includes 
the closest resection margin of the specimen so that both 
lateral and vertical margins could be assessed. The depth 
of tumor invasion (T) is then evaluated along with the 
degree of differentiation and lymphatic or vascular in-
volvement. 
1. Complications
  The complications of endoscopic resection for EGC in-
clude pain, bleeding, and perforation.45 Pain after re-
section is typically mild. Standard dose of proton-pump 
inhibitor is administrated for 4-8 weeks to prevent post-
operative bleeding and to promote ulcer healing.46 For the 
first 24 hours after the procedure, the patient is kept nil 
by mouth, followed by clear liquid on the second day, 
and soft diet for another three days. ESD-induced ulcer is 
reported to heal within 8 weeks after resection under ant-
acid treatment.47
  Bleeding is the most common complication occurring in 
up to 7-8% of patients undergoing standard EMR or 
ESD.48 Immediate bleeding appears more common with 
resections of tumors located on the upper third of the 
stomach. During ESD, immediate minor bleeding is not 
uncommon, but could be successfully treated by grasping 
the bleeding vessels using a hot biopsy forcep with 80W 
soft mode coagulation of ICC 200 (ERBE, Tubingen, 
Fig. 5. Complications during ESD. (A) Arterial bleeding is noticed 
from the exfoliated submucosal layer. (B) Endoscopic hemostasis is 
done by capturing the bleeding vessel. (C) Perforation is noticed 
on the greater curvature of upper body. (D) Endoscopic closure is 
done by using endoclips. (E) Small perforation is noticed. (F) 
Pneumoperitoneum is noticed.
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Germany) (Fig. 5A, B). Endoclips are also often deployed 
for more brisk bleeding. Delayed bleeding, manifested by 
hematemesis or melena at 0-30 days after the procedure, 
is treated by emergent endoscopy using similar techni-
ques. Although most bleeding (75%) occurs within 12 
hours after the procedure, delayed bleeding after ESD oc-
curs in 4-7% which is also strongly related with the loca-
tion and size of the tumor.49
  Perforation is rare in EMR, but is relatively more com-
mon in ESD. The risks of perforation during ESD are 
about 4%.48 Perforations are related with tumor location 
and ulcer findings, but no relationship was found be-
tween perforation and tumor size. Gastric perforation dur-
ing endoscopic resection can be conservatively treated by 
complete endoscopic closure with endoclips (HX-600-090; 
Olympus Co., Tokyo, Japan) when there is no peritoneal 
dissemination.50 This was attempted because the stomach 
is comparatively clean during ESD due to the fasting na-
ture and because of the antibacterial effect of gastric acid 
(Fig. 5C, D). If abdominal fullness due to air leakage 
from the perforated lesion is severe (Fig. 5E, F), decom-
pression of the pneumoperitoneum should be performed 
by 14G puncture needle with side slits after the testing 
using 23G needle syringe filled with saline under the con-
firmation by transabdominal ultrasonography. Nasogastric 
suction should be applied for 12 hours with broad-spec-
trum antibiotic given for 2 days. A diet should be ad-
vanced 3-4 days later. 
  Recently, to prevent gastric perforation, glyceol or so-
dium hyaluronate are used as injection agents.51 These 
makes the ESD procedure easier and safer because these 
agent stay longer in the submucosa and produce clear dis-
section layer. Regarding tissue damage due to the injected 
solution during ESD, sufficient one should be used for 
successful ESD. A combination of hyaluronic acid and 
glycerin solution is the most favorable submucosal in-
jection solution considering tissue damage and sufficient 
lesion-lifting ability.52
CONCLUSION
  In the West, EMR and ESD are not yet widely per-
formed due to the different screening system for early GI 
cancers, relative infrequency of UGI neoplasia, discrepancy 
with Japanese pathological diagnosis, and insufficient per-
ception of the procedures. For all GI cancers, prognosis 
correlates with stage of the disease at diagnosis. With the 
discovery of early GI lesions, EMR and ESD should be at-
tempted considering their relatively low mortality and 
morbidity compared with surgery. 
  EMR and ESD techiques should be considered in the 
West as elective treatment modality for early GI cancers 
as long as it is performed under the right indications by 
an expertise. More experiences are needed to strenghten 
the performance capacity and foster the cooperation 
among skilled endoscopists in Japan and Korea.
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